May 2, 2023 8:00 am EDT MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
May 1, 2023 4:01 pm EDT MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
Apr 14, 2023 7:00 am EDT MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
Apr 13, 2023 7:00 am EDT MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary
Dec 1, 2022 7:30 am EST MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference